Association of Cardiac Pro-β-Type Natriuretic Peptide Levels with Metabolic Risk Factors in Young Obese Egyptian Patients: A Focus on Normotensive vs. Hypertensive Patients

Mona F Schaalan¹, Waild M Mohammad², Mohammed A Hussein³* and Naglaa A Gobba⁴

¹Biochemistry Department, Faculty of Pharmacy, Misr International University, Egypt
²Chemistry Department, Cairo General Hospital, Egypt
³Biochemistry Department, Faculty of Pharmacy, October 6th University, 6th of October City, Giza, Egypt
⁴Pharmacology Department, Faculty of Pharmacy, Misr University for Science & Technology (MUST), October 6 City, Giza, Egypt

Abstract

Objective: In practice, there is increasing recognition of the importance of BNP in the pathophysiology, diagnosis and prognosis of ischemic cardiac dysfunction and heart failure. The association of BNP to obesity and characteristics of the metabolic syndrome in adults and aged patients is well established, but that in pediatrics needs thorough elucidation.

Methods: The aim of this study was to assess the association of plasma β-type natriuretic peptide (BNP) levels and metabolic risk factors in 40 young (average age was 13-17 years) obese normo- and hypertensive patients. This is achieved by assessment of serum levels of glucose, insulin, lipid profile as well as the proinflammatory cytokines, TNF-α, interleukin (IL)-6 and IL-23. The assessed metabolic indicators were compared with that of healthy control young subjects with normal BP (120/80 mmHg).

Results: Contrasting the reported studies in adult persons, the result of the present study showed that β-type natriuretic peptide (BNP) levels are positively associated with characteristics of the metabolic syndrome; Blood pressure, BMI, HOMA index and the lipid profile in both obese groups. The hypertensive obese group exhibited an increased proinflammatory state, leading to the increased levels of serum levels of TNF-α, IL-6 and IL-23, compared to the obese normotensive group.

Conclusion: Early detection of pro-BNP levels in pre-HTN stage is an effective method of prevention of cardiovascular disease. Moreover, proinflammatory mediators, TNF-α, IL-6 should be included in primary screening tests for evaluation of hypertensive patients. However, the prognostic relevance of increased pro-BNP for risk of developing cardiac insufficiency in severely obese patients needs to be further evaluated.

Keywords: Obese normotensive; Hypertensive; Pro-BNP; ICAM; Interleukins and lipid profile

Abbreviations: Pro-BNP: Pro-B Type of Natriuretic Peptide; HOMA-IR, Homeostatic Index of Insulin Resistance; BMI: Body Mass Index; TG: Triglycerides; TC: Total Cholesterol; LDL-c: Low Density Lipoprotein-cholesterol; HDL-c, High Density Lipoprotein-cholesterol; TNF-α: Tumor Necrosis Factor-alpha; IL-6: Interleukin-6; IL-23: Interleukin-23

Introduction

The metabolic syndrome (MetS) is a worldwide problem referred to a constellation of Coronary Heart Disease (CHD) risk factors including obesity and abdominal fat distribution, glucose intolerance, hyperlipidemia, hypertension, reflecting the underlying insulin resistance [1]. The burden of MetS is likely to increase, largely due to decreased physical activity and increased obesity in our society, not only among adults and aged population, but has spread to the young population as well. Although the clinical utility of this designation is controversial [2], there is widespread consensus that it describes a subgroup of individuals with a high risk of cardiovascular disease [3]. Previous studies reported an association between obesity and levels of natriuretic peptides, which are cardiac hormones that played critical roles in vascular remodeling, salt and water homeostasis, and the regulation of vascular tone [4,5].

Brain Natriuretic Peptide (BNP) is synthesized in myocardial cells as a response to increased wall stress in relation to heart failure or acute myocardial ischemia as a prohormone that is cleaved into BNP and N-terminal proBNP (Nt-proBNP). High BNP as well as high Nt-proBNP are new promising Cardiovascular (CV) risk markers and have been associated with high Blood Pressure (BP), Left Ventricular (LV) hypertrophy, and albuminuria [6].

It has been hypothesized that a reduced natriuretic peptide response, called a natriuretic handicap, contributes to the increased susceptibility of obese individuals to fluid retention, hypertension, and heart failure [4]. Despite the well-documented associations between natriuretic peptide levels and obesity [7], data on relations with other metabolic risk factors are controversial. Olsen and colleagues [6] reported an inverse association between N-terminal pro-B-type natriuretic peptide levels and plasma lipids, glucose, and insulin, although the prevalence

*Corresponding author: Prof. Mohammed A. Hussein, Faculty of Pharmacy, October 6th University, 6th of October City, Egypt, Tel: +2 (0122) 48332580; Fax: +2 (02) 38353270; E-mail: Prof.Husseinma@o6u.edu.eg

Received September 10, 2014; Accepted November 25, 2014; Published November 28, 2014

Citation: Schaalan MF, Mohammad WM, Hussein MA, Gobba NA (2014) Association of Cardiac Pro-B-Type Natriuretic Peptide Levels with Metabolic Risk Factors in Young Obese Egyptian Patients: A Focus on Normotensive vs. Hypertensive Patients. J Diabetes Metab 6; 477 doi:10.4172/2155-6156.1000477

Copyright: © 2014 Schaalan MF, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
of metabolic risk factors in that sample was relatively low. Other studies have not found an association between plasma natriuretic peptide levels and hyperlipidemia [8] or hyperglycemia [9]. Low natriuretic peptide levels were associated with each component of the metabolic syndrome except hypertension. Elevated systolic blood pressure was associated with higher natriuretic peptide levels, which likely reflects the hemodynamic influence of blood pressure on natriuretic peptide synthesis [10,11].

Though the childhood obesity turned to an epidemic state, few studies focused on its impact on the level of BNP. As obesity and the metabolic syndrome are known to be related to a state of chronic low grade inflammatory stress state, we sought to elucidate the association of plasma natriuretic peptide levels with metabolic risk factors as well as the proinflammatory cytokines, TNF-α, IL-6 and IL-23, in obese pediatric cohorts in Egypt.

Subjects and Methods

In this prospective non-randomized study, we enrolled 20 obese normotensive and 20 hypertensive young Egyptian patients from the Pediatric Outpatient Clinic at the Endemic Disease Hospital at Cairo University, Egypt. The average age was 13-17 years, including both genders (27 males and 28 females). Informed consent was obtained from all patients and controls. Fifteen volunteers (age and sex matched: 6 females, 9 males) with normal BP (120/80 mmHg) and healthy hemodynamic and biochemical parameters were recruited as a healthy control group. The obese individuals were classified into 2 groups. Group I was composed of 15 young obese normotensive patients (6 females and 9 males) aged 13-17 years. Group II included 20 young obese hypertensive patients (11 females and 9 males), age range 13-17 years. On the other hand, the study protocol was approved by the local ethics committee, and informed written consent was obtained from the parents of the patients and volunteers before entering the study.

Inclusion criteria for both groups were pediatric age (≤ 18 years) when diagnosed with obesity (BMI >20-25); added to normotension according to JNC-7 classification for group I, while hypertension for group II.

Exclusion criteria included presence of autoimmune disease, acute kidney injury or with unsatisfactory vascular access or any other known condition that would alter cytokine levels. Moreover, none of our patients had received antibiotics, anti-inflammatory or corticosteroid medications during the study period.

Clinical assessments included complete history taking, past medical and disease history for confirming the appropriateness of the patients to the inclusion criteria. BP and BMI monitoring were according to the international guidelines.

Blood sampling and biochemical analyses

Venous blood samples were obtained (after overnight fasting) from patients and healthy controls and were divided into two aliquots: one part was anticoagulated and plasma separated for NT-pro-BNP assessment via ELISA according to Maisel et al. [11]. The remainders were allowed to clot and sera were separated by centrifugation (3500 rpm, 20 min, 25°C) and used freshly for determination of serum levels of fasting glucose [12], Insulin [13] and the lipid profile (T-Chol [14], HDL-C [15] and TG (16)) were analyzed using Synchron CX5 autoanalyzer (Beckman, USA) and LDL-cholesterol levels were calculated by using the Falholt et al. formula [17]. Also, pro-inflammatory markers; Tumor Necrosis Factor (TNF)-α [18], interleukin (IL)-6 [19] and interleukin IL-23 [20] using commercially available enzyme-linked immuno-sorbent assay kits (R&D Systems Inc. Minneapolis, MN, USA).

Statistical analysis

All data were expressed as mean ± SD utilizing SPSS 15.0 statistical package for Windows (SPSS Inc., Chicago, IL) [21]. A One-Way Analysis Of Variance (ANOVA) was employed for comparisons of means of the different groups. A p-value < 0.05 was accepted as statistically significant with LSD test as the post –hoc test. Correlation analyses were done using Pearson’s correlation.

Results

Characteristics of the study participants are listed in Table 1; their mean age was 13-17 years. Overall, 20 young obese normotensive young patients (11 females and 9 males), as well as 20 young obese hypertensive patients (11 females and 9 males) were enrolled in the study. According to the JNC-7 classification the obese hypertensive patients in group 2 were classified as stage 1 hypertension. Table 2 shows the progressive elevation of N-BNP levels from obese normotensive to hypertensive individuals. The N-BNP levels in normotensive obese group increased significantly approximately 6-fold (P< 0.01), compared to control group. Moreover, the latter value doubled in the hypertensive obese group. Similar pattern of progressive elevation of glycolytic markers was evident in the levels of glucose, insulin, hence insulin resistance (HOMA IR-index). The lipid profile; TG, TC, LDL-C, HDL-C; showed a 3-fold significant increase in the normotensive obese group, however were not altered in the hypertensive obese group.

The levels of the assessed proinflammatory cytokine markers; TNF-α, IL-6 and IL-23 are presented in Table 3. It shows significantly increased levels of TNF-α, IL-6 and IL-23 (P<0.01), in obese normotensive patients when compared with control healthy individuals group. While the pattern in the obese hypertensive patients shows higher levels (P<0.01), compared to their normotensive counterparts.

Correlations between BNP and the metabolic risk factors

Results of multiple linear regression models relating Log pro-BNP with metabolic risk factors are shown in Table 4. In obese normotensive and hypertensive patients, positive associations were observed between plasma pro-BNP levels and fasting blood glucose (r=0.35), insulin (r=0.31; 0.34), HOMAIR-index (r=0.3; 0.33), TG (r=0.31; 0.34), TC (r=0.21; 0.27), LDL-C (r=0.28; 0.33), HDL-C; showed a 3-fold significant increase in the normotensive obese group, however were not altered in the hypertensive obese group.

The levels of the assessed proinflammatory cytokine markers; TNF-α, IL-6 and IL-23 are presented in Table 3. It shows significantly increased levels of TNF-α, IL-6 and IL-23 (P<0.01), in obese normotensive patients when compared with control healthy individuals group. While the pattern in the obese hypertensive patients shows higher levels (P<0.01), compared to their normotensive counterparts.

Discussion

B-type natriuretic peptide (BNP), a neurohormone synthesized in the cardiac ventricles, is released as preproBNP and then enzymatically

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Control-patients (N=15)</th>
<th>Obese - normotensive patients (N=20)</th>
<th>Obese hypertensive patients (N=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.5 ± 1.45</td>
<td>14.6 ± 1.3</td>
<td>14.8 ± 1.4</td>
<td></td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>80</td>
<td>81.25 ± 2.75</td>
<td>86 ± 3.2*</td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>120</td>
<td>120.75 ± 5</td>
<td>143 ± 8.7**</td>
</tr>
<tr>
<td>BMI</td>
<td>21.2 ± 1.2</td>
<td>21.5 ± 1.2</td>
<td>33.3 ± 0.74**</td>
</tr>
</tbody>
</table>

Values are means ± SD for control healthy, obese normotensive and hypertensive patients groups I and II. Values are statistically significant at *P<0.01. Values are statistically significant at *P<0.001. Values (*) is significantly different from control group; (#) significantly different from normotensive obese patients using one way ANOVA (SPSS program).

Table 1: Participant Characteristics.
Values are means ± SD for control healthy, obese normotensive and hypertensive patients groups (I and II). Values are statistically significant at p<0.01. Values (*) is significantly different from control group; (#) significantly different from normotensive obese patients using one way ANOVA (SPSS program).

Table 2: Plasma Pro-BNP and metabolic parameters in control, obese normotensive and hypertensive patients.

<table>
<thead>
<tr>
<th></th>
<th>Control-patients (N=15)</th>
<th>Obese – normotensive patients (N=20)</th>
<th>Obese hypertensive patients (N=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pro- BNP(pg/ml)</td>
<td>73.06 ± 11</td>
<td>420.2 ± 95.6**</td>
<td>848.25 ± 139.3**</td>
</tr>
<tr>
<td>Glucose (mg/dl)</td>
<td>78.2 ± 4.7</td>
<td>108.4 ± 4.5**</td>
<td>122.9 ± 6.7**</td>
</tr>
<tr>
<td>Insulin(µU/ml)</td>
<td>5.5 ± 0.66</td>
<td>8.8 ± 0.63**</td>
<td>13.2 ± 8.09**</td>
</tr>
<tr>
<td>HOMA IR-index</td>
<td>1.06 ± 0.06</td>
<td>2.34 ± 0.1**</td>
<td>4.00 ± 0.21**</td>
</tr>
<tr>
<td>TG(mg/dl)</td>
<td>75.8 ± 10.36</td>
<td>208.45 ± 21.8**</td>
<td>206.9 ± 27.5**</td>
</tr>
<tr>
<td>TC(mg/dl)</td>
<td>132.06 ± 7.2</td>
<td>301.4 ± 22.7**</td>
<td>301 ± 27.6**</td>
</tr>
<tr>
<td>LDL-C(mg/dl)</td>
<td>77.2 ± 4.7</td>
<td>208.95 ± 18.6**</td>
<td>210.45 ± 19.5**</td>
</tr>
<tr>
<td>HDL-C(mg/dl)</td>
<td>39.73 ± 3.5</td>
<td>50.7 ± 3.57**</td>
<td>49.2 ± 4.1**</td>
</tr>
</tbody>
</table>

Values are means ± SD for control healthy, obese normotensive and hypertensive patients groups (I and II). Values are statistically significant at p<0.05. Values (*) is significantly different from control group; (#) significantly different from normotensive obese patients using one way ANOVA (SPSS program).

Table 3: Serum endothelial and inflammatory markers in control, obese normotensive and hypertensive patients.

<table>
<thead>
<tr>
<th></th>
<th>Control-patients (N=15)</th>
<th>Obese – normotensive patients (N=20)</th>
<th>Obese hypertensive patients (N=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytokine markers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNF-α (ng/ml)</td>
<td>2.3 ± 4.7</td>
<td>7.3 ± 1.9**</td>
<td>29.3 ± 7.6**</td>
</tr>
<tr>
<td>IL-6(ng/ml)</td>
<td>1.2 ± 0.2</td>
<td>5.48 ± 1.1**</td>
<td>17.4 ± 3.0**</td>
</tr>
<tr>
<td>IL-23(ng/ml)</td>
<td>16 ± 3.1</td>
<td>100.6 ± 14.9**</td>
<td>40.5 ± 10.5**</td>
</tr>
</tbody>
</table>

Natriuretic peptides are shown to correlate with measures of cardiac dysfunction. Pro- BNP also has been shown to be an independent risk markers for cardiovascular disease in patients with diabetes [33-35]. The recorded data also suggest that the elevation in pro- BNP in obese normotensive and hypertensive individuals could be largely mediated by insulin resistance, because the obesity relationship was attenuated with adjustment for HOMA-IR in two different epidemiological cohorts. These findings highlight the influence of metabolic factors, particularly insulin resistance, on the Pro- BNP and suggest a potential mechanism for susceptibility to hypertension-related disorders in individuals with insulin resistance [36,37]. The present study revealed that NP levels decrease during acute hyperinsulinemia in patients in normotensive and hypertensive groups. The current results are in alignment with that of Halbirk et al. [38], however have not been replicated by other investigators [39-42]. Obesity still remains the leading cause of coronary heart disease (CHD) in developed countries and control of the cardiovascular disease (CVD) epidemic requires a multifaceted strategy targeting modifiable risk factors for CHD. Although the link between low LDL-cholesterol and the prevention of CVD is well established, many patients remain at risk of CVD despite having LDL-cholesterol levels below recommended targets. Thus, increasing attention is being focused on other lipoprotein fractions, such as HDL and triacylglycerols, as potential targets of therapy. Elevated triacylglycerols levels combined with reduced HDL-cholesterol, referred to as atherogenic dyslipidaemia, are common lipoprotein abnormalities that affect up to 60% of high-risk patients and there is emerging evidence that combined abnormalities of the HDL axis are especially associated with adverse cardiovascular outcomes [43]. The current study revealed significant associations.
between elevation of plasma Pro-BNP and TG, TC and LDL- and HDL-C in obese normotensive and hypertensive patients. The current results suggested that a Pro-BNP level was associated with secondary cardiovascular risk in patients with incident CHD and, therefore, will likely emerge as promising targets for CVD diagnosis. Also, plasma triacylglycerols, LDL- and HDL-cholesterol levels were significantly related to secondary CHD risk independent of a broad range of covariates and traditional risk factors.

Pro-BNP pro-BNP level is currently related to cytokine markers levels (Table 4). Previous studies have investigated a limited numbers of inflammatory markers which have been demonstrated to be related to mainly concentric LVH in hypertensive patients [44,45]. In the present study, several markers of inflammation were studied and higher levels of TNF-α, IL-6 and IL-23 associated with Pro-BNP were observed in obese normotensive and hypertensive patients.

The finding of elevation of pro-BNP and endothelial markers were confirming the active participation of mast cells in the progression of myocardial fibrosis in rats with postmyocarditis-dilated cardiomyopathy [46]. Furthermore, the role of TNF-α, IL-6 and IL-23 in progressive LV dysfunction and remodeling in rats has been previously investigated [47-49]. It was concluded that sustained, pathophysiological relevant circulating concentrations of TNF-α, IL-6 and IL-23 were sufficient to provoke deleterious changes in LV structure and function. The major finding with respect to myocardial function was that a continuous infusion of TNF-α led to a time-dependent depression in LV function that was evident at the level of the intact ventricle as well as in the isolated cardiac myocyte itself [46].

In conclusion, early detection of pro-BNP levels in pre-HTN stage is an effective method of prevention of cardiovascular disease. Moreover, proinflammatory mediators, TNF-α, IL-6 should be integrated to pro-BNP as primary screening tests for and used for the risk stratification for CVD and evaluation of hypertensive patients. However, the prognostic relevance of increased pro-BNP for risk of developing cardiac insufficiency in severely obese patients needs to be further evaluated.

References


